Citalopram News and Research

RSS
Citalopram is an antidepressant drug used to treat major depression associated with mood disorders. It is also used on occasion in the treatment of body dysmorphic disorder and anxiety.
Antidepressant alert – Citalopram associated to heart rhythm disturbances

Antidepressant alert – Citalopram associated to heart rhythm disturbances

New findings from Deplin clinical trial on major depressive disorder presented at NCDEU

New findings from Deplin clinical trial on major depressive disorder presented at NCDEU

AstraZeneca, Targacept commence TC-5214 Phase 2b clinical trial for major depressive disorder

AstraZeneca, Targacept commence TC-5214 Phase 2b clinical trial for major depressive disorder

Psychotic depression: the reason for treatment failure with antidepressants

Psychotic depression: the reason for treatment failure with antidepressants

Forest Pharmaceuticals to pay $300 million as penalty for criminal actions

Forest Pharmaceuticals to pay $300 million as penalty for criminal actions

Study finds selective serotonin reuptake inhibitors not beneficial for autistic children

Study finds selective serotonin reuptake inhibitors not beneficial for autistic children

Antidepressants cannot be recommended in children with autism: Study

Antidepressants cannot be recommended in children with autism: Study

AstraZeneca, Targacept commence enrollment in TC-5214 Phase 3 clinical development for MDD

AstraZeneca, Targacept commence enrollment in TC-5214 Phase 3 clinical development for MDD

AstraZeneca/Targacept's TC-5214 for treatment resistant depression to earn Decision Resources' gold standard status

AstraZeneca/Targacept's TC-5214 for treatment resistant depression to earn Decision Resources' gold standard status

Treatment options available for GAD

Treatment options available for GAD

Some anti-depressant drugs associated with increased chance of developing cataracts: Study

Some anti-depressant drugs associated with increased chance of developing cataracts: Study

SSRIs exhibit anti-inflammatory effects and may provide drug development opportunities for RA

SSRIs exhibit anti-inflammatory effects and may provide drug development opportunities for RA

Medco Health Solutions launches Medco TRC for oncology patients

Medco Health Solutions launches Medco TRC for oncology patients

Targacept signs collaboration and license agreement with AstraZeneca

Targacept signs collaboration and license agreement with AstraZeneca

FDA approves once-daily SEROQUEL XR Extended Release Tablets

FDA approves once-daily SEROQUEL XR Extended Release Tablets

AstraZeneca and Targacept enter into agreement to develop and commercialize TC-5214

AstraZeneca and Targacept enter into agreement to develop and commercialize TC-5214

Targacept presents data from Phase 2b clinical trial of TC-5214

Targacept presents data from Phase 2b clinical trial of TC-5214

Merck update on the status of telcagepant clinical development programs

Merck update on the status of telcagepant clinical development programs

Citalopram no more effective than a placebo for children with autism spectrum disorders

Citalopram no more effective than a placebo for children with autism spectrum disorders

New antidepressants might be no more effective than the best existing drugs

New antidepressants might be no more effective than the best existing drugs